Stay updated on Ad-p53+Xeloda/Anti-PD-1 Safety/Efficacy in Liver Metastases Clinical Trial

Sign up to get notified when there's something new on the Ad-p53+Xeloda/Anti-PD-1 Safety/Efficacy in Liver Metastases Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ad-p53+Xeloda/Anti-PD-1 Safety/Efficacy in Liver Metastases Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The page now presents the Phase 1/2 Ad-p53 trial record, including its terminated status, the note that it is no longer recruiting, and details about its interventions, eligibility criteria, and outcome measures.
    Difference
    60%
    Check dated 2026-11-08T14:55:52.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.2 to v3.8.0. The study page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T15:50:46.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    A banner announces that NIH is transitioning terminology from “Artificial Intelligence” to “Super Intelligence” under Executive Order 14434 and links to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-25T15:14:17.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov error page footer now shows revision v3.7.2 instead of v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-18T15:30:47.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision identifier changes from v3.7.0 to v3.7.1; the page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-11T15:23:20.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error with a standard header, replacing the study record content and indicating that the study details are currently inaccessible.
    Difference
    21%
    Check dated 2026-09-20T16:09:21.000Z thumbnail image

Stay in the know with updates to Ad-p53+Xeloda/Anti-PD-1 Safety/Efficacy in Liver Metastases Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ad-p53+Xeloda/Anti-PD-1 Safety/Efficacy in Liver Metastases Clinical Trial page.